Why use of dienogest for the first contraceptive pill with estradiol?

Gynecological Endocrinology

Volumn 26, Issue 2, 2010, Pages 109-113

  Mueck, Alfred O ^a   Seeger, Harald ^a   Bühling, Kai J ^b  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Contraceptive pill; Dienogest; Estradiol

Indexed keywords

CHLORMADINONE ACETATE; CYPROTERONE ACETATE; DIENOGEST; DIENOGEST PLUS ETHINYLESTRADIOL; DROSPIRENONE; ESTRADIOL VALERATE; NORETHISTERONE; ORAL CONTRACEPTIVE AGENT; SEX HORMONE BINDING GLOBULIN;

DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG USE; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; SHORT SURVEY; STRUCTURE ANALYSIS;

ADOLESCENT; ADULT; CONTRACEPTIVE AGENTS, FEMALE; ENDOMETRIUM; ESTRADIOL; FEMALE; HUMANS; MIDDLE AGED; NANDROLONE; YOUNG ADULT;

EID: 75449105409     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.3109/09513590903184167     Document Type: Short Survey

References (28)

1. Lippert TH,Mueck AO. The clinical importance of dienogest. In: Teichmann AT, editor. Dienogest - preclinic and clinic of a new progestogen. 2nd ed. Berlin, New York: Walter de Gruyter Verlag; 1995. pp 261-274.
2. Oettel M, Elger W, Gräser T, Holz C, Lähteenmäki P, Patchev V. What is past is prologue: estrogen/progestin replacement tomorrow. Gynecol Endocrinol 2001;15(Suppl 4):68-90.
3. Guengerich FP. Inhibition of oral contraceptive steroidmetabolizing enzymes by steroids and drugs. Am J Obstet Gynecol 1990;163:2159-2163.
4. Kuhl H. Pharmacokinetics of oestrogens and progestogens. Maturitas 1990;12:171-197.
5. Köhler G, Faustmann TA, Gerlinger C, Seitz C, Mueck AO. A dose-ranging study to determine the efficacy and safety of dienogest 1, 2, and 4 mg daily in the treatment of endometriosis. Int J Gynecol Obstet, in press.
6. Fruzetti F. Use of natural estradiol in contraception. Contraception, in press.
7. von Schoultz B. Clinical efficacy and safety of combined estradiol valerate and dienogest: a new no-bleed treatment. Climacteric 2003;6(Suppl 2):24-32.
8. Wiegratz I, Hommel HH, Zimmermann T, Kuhl H. Attitude of German Women and gynecologists towards long-cycle treatment with oral contraceptives. Contraception 2004;69:37-42.
9. Zimmerman H, Thebault JJ, Duvauchelle T, Mignot A, Renoux A, Gualano V. Pharmacokinetics of estradiol valerate 2mg + dienogest 2 mg after single and repeated oral administration in healthy postmenopausal women. Clin Drug Invest 2000;20:123-134.
10. Mueck AO, Seeger H. Biochemical markers surrogating on vascular effects of sex steroid hormones. Gynecol Endocrinol 2006;22:163-173.
11. Mueck AO, Seeger H, Lippert TH. Effect of dienogest on the calcium-influx in human cell cultures. In: Teichmann AT, editor. Dienogest - preclinic and clinic of a new progestogen. 2nd ed. Berlin, New York: Walter de Gruyter Verlag; 1995. pp 135-139.
12. Mueck AO, Seeger H, Lü dtke R, Gräser T, Wallwiener D. Effect on biochemical vasoactive markers during postmenopausal hormone replacement therapy: estradiol versus estradiol/ dienogest. Maturitas 2001;38:305-313.
13. Sasagawa S, Shimizu Y, Kami H, Takeuchi T, Shizuka M, Imada K, Kato S, Mizuguchi K. Dienogest is a selective progesterone agonist in transactivation analysis with potent endometrial activity due to its efficient pharmacokinetic profile. Steroids 2008;73:222-231.
14. Saletu B. Sleep, vigilance and cognition in postmenopausal women: placebo-controlled studies with 2 mg estradiol valerate, with and without 3 mg dienogest. Climacteric 2003;6(Suppl 2):37-45.
15. Linzmayer L, Semlitsch HV, Saletu B, Böck G, Saletu- Zyhlarz G, Zoghlami A, Gruber D, Metka M, Huber J, Oettel M, et al. Double-blind, placebo-controlled psychometric studies on the effect of a combined estrogenprogestin regimen versus estrogen alone on performance, mood and personality of menopausal syndrome patients. Drug Res 2001;51:238-245.
16. Oettel M, Gräser T, Hoffman H. Why dienogest as a progestogenic component of postmenopausal nonandrogenic hormone replacement therapy. Drugs Today 2001; 37(Suppl G):3-15.
17. Schneider HP. The role of antiandrogens in hormone replacement therapy. Climacteric 2000;3(Suppl 2):21-27.
18. Köhler G, Gö retzlehner G, Amon I. Therapy of endometriosis with dienogest. Zentralbl Gynäkol 1987;109:795-801.
19. Cosson M, Querleu D, Donnez J, Madelenat P, Konincks P, Audebert A, Manhes H. Dienogest is as effective as triptorelin in the treatment of endometriosis after laparoscopic surgery: results of a prospective, multicenter, randomized study. Fertil Steril 2002;77:684-692.
20. Schindler AE, Christensen B, Henkel A, Oettel M, Moore C. High-dose pilot study with the novel progestogen dienogest in patients with endometriosis. Gynecol Endocrinol 2006; 22:9-17.
21. Harada T, Momoeda M, Taketani Y, Aso T, Fukunaga M, Hagino H, Terakawa N. Dienogest is as effective as intranasal buserelin acetate for the relief of pain symptoms associated with endometriosis - a randomized, double-blind, multicenter, controlled trial. Fertil Steril 2009;91:675-681.
22. Horie S, Harada T, Mitsunari M, Taniguchi F, Iwabe T, Terakawa N. Progesterone and progestational compounds attenuate tumor necrosis factor alpha-induced interleukin-8 production via nuclear factor kappa B inactivation in endometriotic stromal cells. Fertil Steril 2005;83:1530-1535.
23. Fu L, Osuga Y, Morimoto C, Hirata T, Hirota Y, Yano T, Taketani Y. Dienogest inhibits BrdU uptake with G0/G1 arrest in cultured endometriotic stromal cells. Fertil Steril 2008;89:1344-1347.
24. Moore C, Feichtinger W, Klinger G. Clinical findings with the dienogest-containing oral contraceptive Valette1. Drugs Today 1999;35:53-68. (Pubitemid 29342747)
25. Zimmermann T, Dietrich H, Wisser KH, Hoffmann H. The efficacy and tolerability of Valette1: a postmarketing surveillance study. Eur J Contracept Reprod Health Care 1999;4:155-164.
26. Römer T, Gö retzlehner G. Kontrazeption mit OC in 111 Problemfällen, Berlin: Walter de Gruyter; 2008.
27. Nahum GG, Parke S, Wildt L, Efficacy and tolerability of a new oral contraceptive containing estradiol and dienogest. Obstet Gynecol 2008;111:S15.
28. Parke S, Makalova D, Ahrendt H-J, Mansour D. Bleeding patterns and cycle control with a novel four-phasic combined oral contraceptive containing estradiol valerate and dienogest. Eur J Contracept Reprod Health Care 2008;13:94-95.